The DASciS Software for BSI Calculation as a Valuable Prognostic Tool in mCRPC Treated with 223RaCl2: A Multicenter Italian Study

Background/Aim: Radium-223 dichloride ((223)RaCl(2)) represents a therapeutic option for metastatic castration-resistant prostate cancer (mCRPC) patients dealing with symptomatic bone metastases. The identification of baseline variables potentially affecting the life-prolonging role of (223)RaCl(2)...

Descripción completa

Detalles Bibliográficos
Autores principales: De Feo, Maria Silvia, Frantellizzi, Viviana, Bauckneht, Matteo, Farcomeni, Alessio, Filippi, Luca, Rizzini, Elisa Lodi, Lavelli, Valentina, Stazza, Maria Lina, Di Raimondo, Tania, Fornarini, Giuseppe, Rebuzzi, Sara Elena, Filippo, Mammini, Mammucci, Paolo, Marongiu, Andrea, Monari, Fabio, Rubini, Giuseppe, Spanu, Angela, De Vincentis, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10136348/
https://www.ncbi.nlm.nih.gov/pubmed/37189721
http://dx.doi.org/10.3390/biomedicines11041103

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10136348/
https://www.ncbi.nlm.nih.gov/pubmed/37189721
http://dx.doi.org/10.3390/biomedicines11041103

Ejemplares similares